TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Length of Cook Catheter Placement and Induction of Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Women undergoing cervical ripening for labor induction at term (37-41 6/7 weeks) with a singleton gestation in cephalic presentation. Women will need to have a bishop score \<6 or cervical dilation \<2cm with intact membranes to be included.~Exclusion Criteria:~* Non English speaking~* Contraindications to vaginal delivery~* Prior cesarean section

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 6 hour foley (Type: EXPERIMENTAL): The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 6 hours, determined by randomization. At that point health care providers will manage active labor.
- 12 hour foley (Type: NO_INTERVENTION): The participant will have a cook catheter inserted digitally or by direct visualization with a speculum with the uterine component of the balloon inflated to maximum 60mL. The catheter will be taped to the inner thigh with gentle traction. Participants will be started on hospital-based oxytocin protocol. The cook catheter will then be removed at 12 hours, determined by randomization. At that point health care providers will manage active labor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Safety of NovoMix® 30 Treatment for Type 2 Diabetes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- BIAsp 30 (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Observational Registry of the Treatment of Glanzmann's Thrombasthenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with congenital GT defined as patients with lifelong bleeding tendency characterised by impaired or absent platelet aggregation, impaired clot retraction and prolonged bleeding time or prolonged platelet function analyser closure time. The patient has normal platelet counts and platelet morphology. Optional diagnosis criteria are quantitative or qualitative evaluation of GP (Glycoprotein) IIb/IIIa receptor including flow cytometry and identification of gene defects~* Signed informed consent by the patient or next of kin or legally acceptable representative to collect data on treatment of a given bleeding episode or surgical event as specified in the protocol. If informed consent is provided by the next of kin or legally acceptable representative, consent must also be obtained from the patient as soon as he/she is able to do so. Informed consent must be obtained before entry of data into the registry~Exclusion Criteria:~* Patients with acquired thrombasthenic states caused by autoimmune disorders (acute or chronic) or drugs

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
* Ages eligible for study: 12 years and above~* Genders eligible for study: both~* Prior steroid use: steroid-requiring or steroid-free~Inclusion Criteria:~* History of asthma for at least 12 months~* For steriod-requiring patients, documented use of inhaled corticosteroid for at least 4 weeks prior to Screening Visit~* For steroid-free patients, no history of inhaled steroid asthma medication for at least 12 weeks prior to Screening Visit~* Demonstrate FEV-1 of 60-85% of predicted normal values at Screening and Baseline Visit~* Documented reversibility of 15% within 12 months of Screening or at Screening Visit (15% increase from pre-FEV-1 levels following albuterol inhalation or nebulized albuterol administration)~* Symptoms of asthma during Run-in~* Females of childbearing potential must have a negative urine pregnancy test at Screening and Baseline Visits. Females are eligible only if they are not pregnant or lactating, and are either sterile, or using acceptable methods of contraception.~* Must otherwise be healthy~* Provide written informed consent. Wishes of minors must be respected.~Exclusion Criteria:~Patients will not be eligible for the study if they meet any of the following criteria:~* Life-threatening asthma within the past year or during the Run-In Period.~* History of systemic corticosteroid medication within 3 months before the Screening Visit.~* History of omalizumab use within past 6 months.~* History of leukotriene receptor antagonist use, e.g., montelukast, within past week.~* Current evidence or history of any clinically significant disease or abnormality including uncontrolled hypertension, uncontrolled coronary artery disease, congestive heart failure, myocardial infarction, or cardiac dysrhythmia.~* Upper or lower respiratory infection within 4 weeks prior to Screening Visit or during Run-In Period.~* Significant, non-reversible, pulmonary disease (e.g., chronic obstructive pulmonary disease \[COPD\], cystic fibrosis, bronchiectasis).~* Known Human Immunodeficiency Virus (HIV)-positive status.~* Smoking history equivalent to 10 pack years.~* Current smoking history within 12 months prior to Screening Visit.~* Current evidence or history of alcohol and/or substance abuse within 12 months prior to Screening Visit.~* Patients who are confined in institution.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): FlutiForm 100/10ug
- 2 (Type: EXPERIMENTAL): Fluticasone 100
- 3 (Type: ACTIVE_COMPARATOR): Formoterol 10

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Palatability of Oral Rehydration Solutions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children 5-10 years of age evaluated in The Hospital for Sick Children's emergency department~Exclusion Criteria:~* Children with diarrhea, a vomiting or diarrhea episode within 24 hours, head trauma, abdominal pain, upper respiratory symptoms, or nil per os status~* Patients with gastrointestinal symptoms

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Taking at least three medications for blood pressure (one a diuretic)~* Uncontrolled high blood pressure~* Abnormal kidney function (with-eGFR, a measure of kidney function, of 25 - ≤ 45 mL/min/1.73m2~* Normal Blood serum Potassium in a specific range (4.3 - 5.1 mEq/L)~Exclusion Criteria:~* History of untreated known causes of high blood pressure, excluding kidney disease (not CKD)~* Inability to measure BP~* Not taking high blood pressure medications as prescribed medications~* Recent change in renal function (in the past 3 months) which has required hospitalization or dialysis~* Renal transplant~* History of cancer within past 12 months~* Recent cardiovascular event with last 3 months~* Clinically significant abnormalities of heart rhythm (ventricular arrhythmia or atrial fibrillation with uncontrolled heart rate)~* Inability to take study medication~* Alcoholism

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 - Patiromer (Type: EXPERIMENTAL): spironolactone + blinded patiromer
- Group 2 - Placebo (Type: EXPERIMENTAL): spironolactone + blinded placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed squamous cell lung cancer~* Newly diagnosed untreated Stage IV and/or recurrent after adjuvant therapy with metastatic disease~* Patients previously treated with immune checkpoint inhibitor therapy are eligible~* Measurable disease as per RECIST 1.1~* Greater than 6 months since receiving neo-adjuvant or adjuvant chemotherapy.~* Age ≥ 18 years~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Women of childbearing potential and sexually active men enrolled in the study must agree to practice effective contraception method during treatment and for three months after completing treatment~* Negative serum or urine β-hCG pregnancy test at screening for patients of childbearing potential~* \< Grade 2 pre-existing peripheral neuropathy (per CTCAE)~* Marrow and organ function as follows:~* ANC ≥ 1500 cells/mm3~* Platelets \> 100,000 cells/mm3~* Hemoglobin\>9g/dL~* Creatinine clearance ≥ 40mL/min~* Bilirubin ≤ 1.5 mg/dL~* AST/ALT≤2.5 x upper limit of normal range (ULN),~* alkaline phosphatase ≤ 2.5 X upper limit of normal, unless bone metastasis in present in the absence of liver metastasis~Exclusion Criteria:~* Prior treatment with albumin-bound paclitaxel or gemcitabine~* Prior systemic anticancer therapy for advanced squamous cell lung cancer~* Untreated brain metastasis. Patients with treated brain metastases who are off steroids are eligible~* Peripheral neuropathy greater than grade 1~* Malignancies within the past 5 years other than non-melanoma skin cancer or insitu cervical cancer status post treatment~* Patients with other serious medical illnesses including, ongoing or active infection, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements~* Class III or IV congestive heart failure by New York Heart Association

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albumin-Bound Paclitaxel and Gemcitabine (Type: EXPERIMENTAL): During each 21-day cycle, albumin-bound paclitaxel at 100mg/mg2 over 120 minutes and gemcitabine at 1000mg/m2 over 30 minutes will be given intravenously on days 1 and 8 of each 21 day cycle. Treatment will continue until disease progression or intolerable side effects. After the 4th cycle of treatment, patients will have the option of discontinuing gemcitabine and proceeding with weekly albumin-bound paclitaxel as maintenance therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Successfully implanted Linox Lead System connected to a BIOTRONIK ICD, from 1-45 days prior to enrollment~* Able to understand the nature of the registry and provide informed consent~* Available for follow-up visits on a regular basis at the investigational site~* Age greater than or equal to 18 years~Exclusion Criteria:~* Enrolled in any IDE clinical study~* Planned cardiac surgical procedures or investigational measures within the next 6 months~* Expected to receive a heart transplant within 1 year~* Life expectancy less than 1 year~* Presence of another life-threatening, underlying illness separate from their cardiac disorder~* Pregnancy~* Inability to provide date of implant, devices implanted, age, gender, and whether the patient experienced any protocol-defined adverse events since implant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Data Collection Group (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cirrhosis with TIPS for ascit treatment or hydrothorax~* prevention digestive bleeding follow up portal hypertension -~* signed consent~Exclusion Criteria:~* hepatocellular carcinoma out of Milan criteria or palliative phase cancer~* Child Pugh score \> 12~* TIPS indicated for other indication than bellow~* encephalopathy signs : asterixis or confusion~* Hypersensibility to rifaximin, or derivated of rifamycin~* Patients treated by same class antibacterial~* pregnant woman~* Patient with hepatic transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- rifaximin (Type: EXPERIMENTAL): 6 rifaximin caps of 200 mg per day morning and night, during 15 days before TIPS, and after TIPS during 6 months.
- placebo (Type: PLACEBO_COMPARATOR): 6 caps placebo morning and night, 15 days before and 6 months after TIPS

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject having given her/his informed, written consent.~  * Subject cooperative and aware of the modalities of use and the necessity and duration of the controls so that perfect adhesion to the protocol can be expected.~ * Subject being psychologically able to understand information and to give their/his/her consent.~ * Age: more than 18 years.~ * Subject with superficial onychomycosis on at least one great toenail or light to moderate disto-lateral onychomycosis (without matrix involvement and involvement \<2/3 of the tablet).~ * Subject with positive KOH staining.~ * Subject having stopped any systemic antifungal treatment since at least 6 months before inclusion and/or any topical antifungal treatment since at least 3 months before inclusion.~ * Female subjects of childbearing potential should use an accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after study end.~Exclusion Criteria:~* Subject considered by the Investigator likely to be non-compliant with the protocol.~* Patient enrolled in another clinical trial during the test period.~  · Woman being pregnant, nursing or planning a pregnancy during the course of this study.~* Subject having a known allergy to one of the constituents of the tested products.~* Patient suffering from serious or progressive diseases (to investigator's discretion) such as uncontrolled diabetes, peripheral circulatory disease, HIV, psoriasis, lichen planus, immunosuppressive pathology...~* Subject with cutaneous pathology on studied zone (other than onychomycosis like angioma, dermatitis...).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Excilor Forte (Type: EXPERIMENTAL): One application of the MD daily (at same time point), preferably after showering/bathing, during the complete study period.
- Loceryl 5% (Type: ACTIVE_COMPARATOR): One application per week of the positive control Loceryl 5% during the whole study period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bevacizumab (Avastin) in Women With HER2 Negative Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Female patients ≥ 18 years of age.~* Human epidermal growth factor receptor 2 (HER2)-negative cancer of the breast with locally recurrent or metastatic disease, suitable for chemotherapy.~* No adjuvant chemotherapy within 6 months before randomization, and no taxane-based chemotherapy within 12 months before randomization.~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.~Exclusion criteria:~* Previous chemotherapy for metastatic or locally recurrent breast cancer.~* Radiotherapy for treatment of metastatic disease.~* Other primary tumors within last 5 years, except for controlled limited basal cell or squamous cancer of the skin, or cancer in situ of the cervix.~* Spinal cord compression or brain metastases.~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization.~* Inadequate bone marrow, liver, or renal function.~* Uncontrolled hypertension.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel 100 mg/m^2 plus placebo (Type: EXPERIMENTAL): Participants received docetaxel 100 mg/m\^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received placebo to bevacizumab intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
- Docetaxel 100 mg/m^2 plus bevacizumab 7.5 mg/kg (Type: EXPERIMENTAL): Participants received docetaxel 100 mg/m\^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 7.5 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.
- Docetaxel 100 mg/m^2 plus bevacizumab 15.0 mg/kg (Type: EXPERIMENTAL): Participants received docetaxel 100 mg/m\^2 intravenously on Day 1 of each 3 week cycle for a maximum of 27 weeks (9 cycles). In addition, participants received bevacizumab 15.0 mg/kg intravenously on Day 1 of each 3 week cycle until disease progression, unacceptable toxicity, or participant withdrawal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bleed Free Treatment of Menopausal Symptoms With New Ultra Low Dose Hormonal Combinations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal status~* Subject should have had a minimum of 7 moderate to severe hot flushes per day, or a minimum of 50 moderate to severe hot flushes per week, during the last 2 weeks of the run-in (screening) period.~* Subject with an intact uterus~Exclusion Criteria:~* In accordance with existing labelling for estrogen/progestogen combinations~* Body Mass Index (BMI) \> 35.0 kg/m2~* Known alcohol or drug abuse, heavy smoking (more than 20 cigarettes a day)~* Currently using steroid hormones (except topical or inhalation glucocorticoid preparations) and drugs known to influence estrogen metabolism such as barbiturates, phenytoin, rifampicin, carbamazepin

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ALD 0.1 (Type: EXPERIMENTAL): None
- ALD 0.25 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete